Idera Pharmaceuticals News
Idera Pharmaceuticals, Inc. (IDRA) Posts Q1 Loss of 15c/Share
Street Insider May 15Idera Pharmaceuticals Reports First Quarter 2013 Financial Results
Business Wire May 15Idera Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2013.
Idera Pharma (IDRA) Issues Encouraging Update from IMO-3100 Phase 2
Street Insider May 8Idera Announces Presentation of Positive Data from Phase 2 Trial of TLR 7 and 9 Antagonist in Patients with Moderate-to-Severe Plaque Psoriasis
Business Wire May 8Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.
Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants
Business Wire May 1Idera Pharmaceuticals today announced the pricing of an underwritten public offering by Idera Pharmaceuticals of for a combined public offering price of $0.50 per share of common stock and related warrant, 17,500,000 shares of common stock and related warrants to purchase up to 17,500,000 shares of common stock at an exercise price of $0.47 per share, and for a combined public offering price of $0.49 ...
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IDRA | 0.70 | +0.03 | +4.48% | 19.36M |
